viernes, 25 de julio de 2014

CDC - Teen Vaccination Coverage - NIS – Teen - Vaccines

CDC - Teen Vaccination Coverage - NIS – Teen - Vaccines

Press Release
Thursday, July 24, 2014                                                                                                            
 Safe and effective vaccine that prevents cancer continues to be underutilized
Latest vaccination coverage estimates for adolescents show only small increase for HPV vaccine
CDC officials announced today that the number of girls and boys aged 13-17 years receiving human papillomavirus (HPV) vaccine remains unacceptably low despite a slight increase in vaccination coverage since 2012, according to data from CDC′s 2013 National Immunization Survey-Teen (NIS-Teen) published in this week′s Morbidity and Mortality Weekly Report (MMWR).

Teen Vaccination Coverage

2013 National Immunization Survey-Teen (NIS-Teen)

Summary of Main Points

From 2012 to 2013, there were modest increases in vaccination coverage among U.S. adolescents between the ages of 13 and 17 years for all vaccines routinely recommended for preteens and teens. However, progress is occurring at an unacceptably slow pace for HPV vaccination. Vaccination coverage estimates for human papillomavirus (HPV) vaccination remained low in 2013.

2013 HPV Vaccination Coverage for Adolescents

2012 HPV Vaccination Coverage for Girls.
The newest data showing coverage rates of HPV vaccine for adolescents 13-17 years of age were published July 24, 2014 in MMWR.
We have found that many preteens and teens are not getting HPV vaccine when they receive other recommend vaccines; 91.3% of 13 year old girls would have received at least one dose HPV vaccine if they had received a HPV vaccine at the same time they received other recommend vaccines. Instead, coverage for girls ages 13-17 who received at least one dose of HPV vaccine was 57.3%.
The Advisory Committee on Immunization Practices (ACIP) recommends that preteens (ages 11 or 12) get one dose of Tdap, meningococcal, and HPV vaccines during a single visit. A persistent gap in coverage between HPV vaccination and other vaccinations recommended for adolescents is a sign of missed opportunities to protect adolescents from HPV-related cancers. Since 2008, the yearly national vaccination coverage estimate among female teens for one dose of HPV vaccine has been lower than the estimate for one dose of Tdap vaccine, and the difference in coverage between the two vaccines remains large. The difference between Tdap and HPV vaccine show valuable opportunities are being missed to vaccinate boys and girls, leaving them at greater risk of HPV infections that can lead to cancer.

Survey Data – Coverage among Adolescents 13 through 17 Years of Age

HPV Vaccine

  • For girls who received at least one dose of HPV vaccine, coverage increased between 2012 and 2013 (53.8% in 2012 vs. 57.3% in 2013).
    • Receipt of the recommended three doses increased, but still remained low from 2012 to 2013 (33.4% in 2012 compared to 37.6% in 2013).
    • Among girls who received one, two, or three doses of HPV vaccine, coverage rates were higher for Hispanics than for whites.
    • Overall, coverage for one or two doses of HPV was higher for girls living below the poverty level; however, no differences by poverty level were observed for three doses.
    • HPV 3-dose series completion was similar between white and Hispanic girls, but was lower among Black adolescent females. This means among teen girls who started getting HPV vaccinations, Black girls were less likely than white or Hispanic girls to finish getting all the recommended doses.
  • For boys, there was a 13.8 percentage point increase for at least one dose of HPV vaccine (from 20.8% in 2012 to 34.6% in 2013)
    • 13.9% of boys aged 13-17 years received all three recommended doses of HPV vaccine in 2013 (compared to 6.8 % in 2012).
    • Coverage for one, two, or three doses of HPV vaccine was greater among black and Hispanic boys compared to whites.
    • Overall, coverage for all doses of HPV vaccine was greater among boys living below the poverty level compared to those living at or above the poverty level.
  • National vaccination coverage data reflect a wide variation in coverage at the state level.
    • For girls who received at least one dose of HPV vaccine, state coverage ranged from 39.9% in Kansas to 76.6% in Rhode Island.
    • For boys who received at least one dose of HPV vaccine, state coverage ranged from 11.0% in Kansas to 69.3% in Rhode Island.

Meningococcal Conjugate Vaccine

  • Meningococcal vaccination coverage continued to increase among 13-17 year olds. There was a 3.8 percentage point increase, going from 74.0% in 2012 to 77.8% in 2013.
  • Among 17 year old adolescents who received a first dose before turning 16, 29.6% of them received the recommended second dose of meningococcal vaccine in 2013.
    • This is the first year coverage data is available for the second dose of meningococcal vaccine. ACIP first recommended a second dose of meningococcal vaccine for all teens in October 2010.

Tdap Vaccine

  • Nationally, Tdap vaccination coverage increased by 1.4 percentage points from 2012 to 2013 (84.6% in 2012 vs. 86.0% in 2013) among children 13-17 years.
  • 42 states met the Healthy People 2020 adolescent vaccination coverage target of 80% for at least one dose of Tdap among adolescents 13-15 years, up from 36 states in 2012.

NIS-Teen Vaccination Coverage Data Tables

Background on the NIS-Teen

  • The National Immunization Survey on teen vaccination coverage rates (also called NIS-Teen) provides a "report card" to let us know how well we are doing in protecting our nation's teens against vaccine-preventable diseases.
  • The NIS-Teen includes vaccination coverage estimates for three vaccines that are recommended at 11 through 12 years of age. These vaccines include Tdap to protect against tetanus, diphtheria, and pertussis, meningococcal vaccine to protect against meningococcal disease, and HPV vaccine to protect against infection with HPV and HPV-related diseases, including certain types of cancers.
  • The NIS-Teen is a random-digit-dialed telephone survey of parents and guardians of teens 13–17 years old; in 2013, it included data for more than 18,000 adolescents. The telephone survey is followed by collection of vaccination records from clinicians.
  • NIS-Teen immunization coverage estimates are based on a sample of adolescents identified from both land-line and cell phone sampling frames. Before 2011, only land-line sampling frames were used.  Including cell phones helps keep a nationally representative sample, since an increasing number of families have started using only cell phones and no longer have land-line telephones.
  • The report also includes coverage on some vaccines recommended for adolescents if not previously given in childhood.

No hay comentarios:

Publicar un comentario